AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Phase 3
Not yet recruiting
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06512883
- Locations
- 🇹🇷
Research Site, Altındağ, Turkey
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Budenoside/Glycopyrronium/Formoterol
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT06511193
- Locations
- 🇨🇦
Research Site, Windsor, Ontario, Canada
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Phase 3
Recruiting
- Conditions
- Asthma
- Interventions
- Drug: Placebo MDI HFADrug: BDA MDI HFO 160/180 μgDrug: BDA MDI HFA 160/180 μg
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 398
- Registration Number
- NCT06502366
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD8965Other: Placebo
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 135
- Registration Number
- NCT06502379
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Study to Assess the Pharmacokinetics of AZD6793 When Administered Alone and in Combination With Itraconazole in Healthy Participants.
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT06494644
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsRespiratory Tract DiseasesLung NeoplasmsNeoplasmsCarcinoma, BronchogenicLung DiseasesThoracic NeoplasmsNeoplasms by SiteBronchial Neoplasms
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06494241
- Locations
- 🇨🇳
Research Site, Zhuji, China
NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
Recruiting
- Conditions
- Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06494540
- Locations
- 🇩🇪
Research Site, Wiesbaden, Germany
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD4144- Part BDrug: Rosuvastatin- Part CDrug: Rosuvastatin and AZD4144 Part CDrug: Placebo- Part ADrug: AZD4144- Part ADrug: Placebo- Part B
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 92
- Registration Number
- NCT06491550
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
Recruiting
- Conditions
- Non-squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06491862
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT06487065
- Locations
- 🇪🇸
Research Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath